Description

HD Tirsema 44 Pen: Dual Peptide Weight Loss Injection

The HD Tirsema 44 Pen is a weekly subcutaneous injection containing 40 mg tirzepatide plus 4 mg semaglutide in a single device, marketed in South Africa via Beskinny at R2400 per pen as of 2026 [1]. It targets adults who have already trialled single-peptide GLP-1 therapy and want a stronger combined GLP-1 and GIP receptor stimulus in one shot rather than two separate pens — the dual-receptor activation produces broader appetite suppression than either peptide alone.

That combination works by shifting receptor occupancy. Tirzepatide is already a dual GIP/GLP-1 agonist with deliberately lower GLP-1 receptor engagement than pure semaglutide [6], so stacking 4 mg semaglutide on top raises the GLP-1 signal while leaving the GIP arm intact.

Key Takeaways

• Tirsema 44 combines 40 mg tirzepatide and 4 mg semaglutide for dual GIP/GLP-1 receptor activation, best suited for users who have plateaued on single-peptide therapy
• No peer-reviewed human trial of concurrent tirzepatide + semaglutide has been published; the dual-pen rationale rests on receptor-pharmacology inference
• Conservative titration over 16+ weeks, starting at 2.5 mg equivalent weekly, is recommended; the practical ceiling is usually lower than tirzepatide monotherapy due to dual-agonist saturation
• GLP-1-naive users, those with prior severe GI side effects, and anyone with a history of medullary thyroid carcinoma or pancreatitis should not use this pen
• Storage requires 2–8°C refrigeration until first use, then below 30°C for the in-use period; freezing irreversibly damages both peptides

What Is the HD Tirsema 44 Pen?

The HD Tirsema 44 Pen is a once-weekly subcutaneous injection from HD Labs containing 44 mg of combined peptides per pen: 40 mg tirzepatide and 4 mg semaglutide, delivered via a prefilled multi-dose pen for dual GIP and GLP-1 receptor stimulation aimed at appetite suppression and metabolic support [1]. It is sold in South Africa through Beskinny at R2400 per pen as of 2026 [1].

The 44 mg total peptide load is the highest in HD Labs' weight-loss pen range as of 2026. It sits above single-peptide options like the HD Labs Tirzepatide 30 Pen and cross-brand equivalents such as the Body Pharm Tirzepatide 30 Pen [1]. The "44" in the product name refers directly to that combined milligram total, not a concentration or strength grade.

Why Combine Tirzepatide and Semaglutide?

Combining tirzepatide and semaglutide produces broader signalling coverage than either alone because the two peptides activate appetite-suppressing receptors with different binding profiles.

Tirzepatide is a dual GIP/GLP-1 agonist biased toward GIP, meaning its GLP-1 receptor engagement is partial relative to a selective GLP-1 agonist at comparable doses [2]. Semaglutide is a selective GLP-1 agonist. Adding it raises GLP-1 receptor occupancy in the hypothalamus and brainstem nuclei that govern satiety and nausea-mediated intake reduction. These brain regions contain high densities of GLP-1 receptors that respond to dose-dependent occupancy.

The individual evidence base is strong but separate. Tirzepatide's weight-loss efficacy was established in SURMOUNT-1 (NEJM, 2022), which reported up to ~20.9% mean body-weight reduction at the 15 mg weekly dose over 72 weeks [3]. Semaglutide's was established in the STEP-1 trial programme (NEJM, 2021) at 2.4 mg weekly. No peer-reviewed human trial of concurrent tirzepatide + semaglutide administration has been published as of 2026 [1]. The dual-pen rationale rests on receptor-pharmacology inference, not head-to-head outcomes data. That gap matters when deciding between Tirsema 44 and a single-peptide option like the HD Labs Tirzepatide 30 Pen or the Body Pharm Tirzepatide 30 Pen.

Where the combination logic could break down

Some researchers argue that because tirzepatide already activates the GLP-1 receptor, layering semaglutide adds redundancy rather than a distinct pathway [2]. The counter-argument rests on the GIP-bias point above: partial GLP-1 occupancy leaves room for an additive selective agonist because the receptor is not saturated at tirzepatide's typical doses. Both positions are currently theoretical pending direct combination-trial data.

HD Tirsema 44 vs Single-Peptide Pens

Choose Tirsema 44 only if you've already run a full titration on a single-peptide GLP-1 and stalled. For first-time users, a tirzepatide-only pen is the safer entry point because it allows tolerance to build to one peptide before adding a second. The table below sets out how the four pens stocked on Beskinny differ on peptide content, receptor targets, and intended user.

Who should not start with Tirsema 44

GLP-1-naive users, anyone with a prior history of severe GI side effects (persistent vomiting, pancreatitis), and users who have not completed at least 8–12 weeks on a single-peptide pen should not begin here. The dual-peptide load raises GLP-1 receptor occupancy beyond what tirzepatide alone delivers [4], which amplifies nausea risk in opioid-naive titration because the hypothalamus becomes more sensitised to satiety signals. The full HD Labs single-peptide range is browsable at beskinny.store/product-category/brands/hd-labs/ if a lower-intensity starting point fits your profile better.

Dosing Protocol and Escalation Schedule

No HD Labs Tirsema 44 product insert is publicly available as of 2026, so the schedule below is extrapolated from branded tirzepatide prescribing information [2] and standard semaglutide titration practice [7]. Confirm starting dose, step-up intervals, and maximum with your dispensing pharmacist at the point of purchase.

A conservative weekly escalation, in tirzepatide-equivalent terms, mirrors the Zepbound 2024 label [2]:

1. Weeks 1–4: 2.5 mg equivalent once weekly. Tolerance check, not a therapeutic dose.
2. Weeks 5–8: 5 mg equivalent once weekly.
3. Weeks 9–12: 7.5 mg equivalent once weekly if GI symptoms are controlled.
4. Weeks 13–16: 10 mg equivalent once weekly.
5. Week 17 onward: Step to 12.5 mg or 15 mg equivalent only under clinician supervision. The combined GLP-1 load from semaglutide means the practical ceiling is usually lower than tirzepatide monotherapy at the HD Labs Tirzepatide 30 Pen or Body Pharm Tirzepatide 30 Pen equivalent dose. Dual-agonist saturation occurs at lower absolute tirzepatide milligrams.

Injection sites and missed doses

Rotate between abdomen (avoiding a 5 cm radius around the navel), front of thigh, and back of upper arm. Don't inject the same spot two weeks running — repeated injection at one site can cause lipohypertrophy, reducing absorption. If a dose is missed and the next scheduled dose is more than 72 hours away, take it as soon as possible. If less than 72 hours away, skip it and resume the normal weekly schedule [2].

Managing GI side effects

Mild to moderate nausea peaks in the 48 hours after injection and usually settles by week 3 of each new dose [2]. The body adapts to sustained GLP-1 receptor occupancy over this period. Eat smaller, lower-fat meals, stay hydrated, and hold escalation if vomiting or diarrhoea persists beyond 72 hours. Severe abdominal pain radiating to the back warrants stopping the pen and seeking medical review for suspected pancreatitis. Acute pancreatitis is a rare but serious adverse event linked to GLP-1 agonists.

This protocol is informational. A registered prescriber in South Africa must authorise your titration; tirzepatide and semaglutide are Schedule 4 medicines [4].

Storage, Handling, and Shelf Life

Store the HD Tirsema 44 Pen in a fridge at 2–8°C until first use, then keep it below 30°C and away from direct light for the in-use period. Do not freeze the pen. Freezing damages both peptides irreversibly because ice crystal formation disrupts the tertiary structure of the protein molecules. A thawed pen should be discarded even if it looks normal.

Most GLP-1 peptide pens carry a 28–30 day in-use stability window at room temperature based on standard pharmaceutical guidance for tirzepatide and semaglutide products [2][5]. The HD Labs Tirsema 44 insert is not publicly accessible, so verify the printed expiry and in-use window on your specific pen before relying on this figure.

Visual checks before each dose

The solution should be clear and colourless. Discard the pen if you see cloudiness, floating particulates, a yellow or brown tint, or if the cartridge has been left above 30°C for longer than 24 hours. These signs indicate peptide degradation or contamination. A pen that has been frozen, dropped hard, or left in a hot car should not be injected.

Travel and dispatch

For travel, carry the pen in an insulated pouch with a cool pack (not in direct contact with ice) and keep it in cabin luggage, never in the hold where temperatures can drop below freezing. Beskinny dispatches HD Labs pens with cold-chain packaging from Johannesburg, which preserves the 2–8°C range during typical 1–3 day courier transit within South Africa [1]. Refrigerate immediately on arrival. If you are comparing storage practicalities against single-peptide options, the HD Labs Tirzepatide 30 Pen and Body Pharm Tirzepatide 30 Pen follow the same cold-chain and in-use handling rules.

Who Should Use the Tirsema 44 Pen?

The Tirsema 44 pen is designed for adults who have already trialled a single-peptide GLP-1 or dual GIP/GLP-1 therapy for 8–12 weeks and have not reached their target weight or metabolic goals. The dual-peptide approach offers a mechanistic step-up when monotherapy plateaus. If you are GLP-1 naive, starting with the HD Labs Tirzepatide 30 Pen or Body Pharm Tirzepatide 30 Pen is the more sensible entry point, since both peptides in Tirsema 44 sit at the upper end of the dosing range.

Candidate profile

The underlying peptides were studied in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia (SURMOUNT-1, 2022; STEP-1, 2021) [3]. Tolerating weekly subcutaneous injections is a baseline requirement because the medication cannot be taken orally.

Not suitable for

Tirsema 44 is not suitable for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome because GLP-1 agonists may stimulate C-cell proliferation in the thyroid. It is also unsuitable for those with a prior episode of pancreatitis (the risk of recurrence is elevated with GLP-1 therapy), current pregnancy or breastfeeding, or known hypersensitivity to tirzepatide or semaglutide [2][5]. Adults under 18, and those with severe gastroparesis or active gallbladder disease, should avoid it because these conditions are worsened by delayed gastric emptying or biliary stasis.

Discuss the pen with a doctor or pharmacist registered in South Africa before ordering, since both peptides are Schedule 4 medicines requiring a prescription [4].

How to Buy the HD Tirsema 44 Pen in South Africa

Order the HD Tirsema 44 Pen directly from beskinny.store at R2400 per pen (price current as of 2026, subject to change) [1]. Add to cart, check out with card or EFT, and your pen ships nationwide across South Africa in discreet cold-chain packaging, typically dispatched within 1–2 business days of payment clearing.

Beskinny is a dedicated weight-loss peptide retailer stocking HD Labs, Body Pharm, and other compounded brands. Browse the full weight-loss injections category or the HD Labs brand page to compare before committing. Single-peptide buyers usually weigh up the HD Labs Tirzepatide 30 Pen or Body Pharm Tirzepatide 30 Pen. For triple-receptor or amylin pathways, HD Labs Retatrutide 32 and Body Pharm Cagrisema 12 sit in the same catalogue.

Frequently Asked Questions

Is the Tirsema 44 Pen the same as Mounjaro or Ozempic?

No. Mounjaro is branded tirzepatide from Eli Lilly and Ozempic is branded semaglutide from Novo Nordisk, each a single peptide. Tirsema 44 is a compounded HD Labs pen combining 40 mg tirzepatide with 4 mg semaglutide in one device, sold under South African Schedule 4 compounding rules rather than as a SAHPRA-registered brand [8].

Can I use Tirsema 44 if I have never used a GLP-1 before?

It is not the recommended starting point for naive users. The combined GIP and GLP-1 receptor load at 40 mg + 4 mg sits well above typical initiation doses. First-time users usually begin on a lower-dose single peptide like the HD Labs Tirzepatide 30 Pen and step up only after tolerating 2.5–5 mg tirzepatide weekly [2]. That approach allows the body to adapt to GLP-1 signalling before exposure to dual-agonist saturation.

How long does one pen last?

At a weekly maintenance dose drawn from the 44 mg total payload, one Tirsema 44 pen typically covers 4–8 weeks depending on where you sit in the titration schedule. Early titration weeks at lower doses stretch the pen further. Maintenance dosing at the upper end shortens it because higher weekly draws deplete the cartridge faster.

What is the difference between Tirsema 44 and HD Labs Tirzepatide 30?

Tirsema 44 contains 40 mg tirzepatide plus 4 mg semaglutide. The HD Labs Tirzepatide 30 Pen contains 30 mg tirzepatide only. The 30 pen activates GIP and GLP-1 receptors via one molecule. Tirsema 44 adds a second, longer-acting GLP-1 agonist for stronger GLP-1R occupancy alongside GIP activity [4]. Semaglutide has a longer half-life than tirzepatide's GLP-1 component, extending receptor engagement between weekly doses.

Does Beskinny ship the Tirsema 44 pen cold?

Yes. Beskinny dispatches the Tirsema 44 pen nationwide in discreet cold-chain packaging, typically within 1–2 business days of payment clearing [1].

Next Steps

If you have already completed 8–12 weeks on a single-peptide GLP-1 and have plateaued, consult a registered South African prescriber to discuss whether Tirsema 44 is appropriate for your profile. If you are new to GLP-1 therapy, start with the HD Labs Tirzepatide 30 Pen or Body Pharm Tirzepatide 30 Pen and titrate gradually over 16 weeks before considering a dual-peptide step-up. Either way, order from beskinny.store and confirm your prescription status with the dispensing pharmacist before checkout.